Nuvectis Pharma, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, disclosing financial results and operational details for the three and nine months ended September 30, 2026.

Key Highlights

  • Shares outstanding: 34,388,908 shares of common stock, $0.00001 par value, were outstanding as of October 30, 2026.
  • No revenue generated: According to the filing, the company has not generated any revenue to date.
  • Continued losses expected: The company disclosed it has incurred losses since inception and expects to incur continued losses for the foreseeable future.
  • Three product candidates: The filing identifies NXP100, NXP200, and NXP900 as the company's current product candidates, with no pivotal trials completed to date.
  • Additional capital required: The company disclosed it will require substantial additional capital to finance operations and achieve its goals.
  • Filer classification: Nuvectis Pharma is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Nuvectis Pharma Reports Third-Quarter 2026 Financial Position and Pipeline Status

Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage pharmaceutical company headquartered in Fort Lee, NJ, submitted its quarterly report covering the period ended September 30, 2026. The filing identifies the company's three product candidates - NXP100, NXP200, and NXP900 - as the primary focus of its development activities. According to the filing, the company has only initiated a limited number of clinical trials and has not completed any pivotal trials to date.

The company reported that it has not generated any revenue since inception and continues to incur operating losses. The filing states that the ability to generate revenue and achieve profitability "depends significantly on our ability to achieve several objectives relating to the discovery or identification, preclinical and clinical development, regulatory approval, and commercialization of our current or future product candidates." The company disclosed that it will require substantial additional capital and that failure to raise such capital could force it to "delay, reduce, or eliminate" research or product development programs.

The filing also highlights several risk factors specific to the company's operations. These include reliance on Haisco, described as the in-licensing partner for NXP100 and NXP200, for technology transfer and supply of certain materials. The company further noted that regulatory changes affecting drugs originating in China could adversely affect development plans for NXP100 and NXP200. The filing additionally cited potential risks from tariffs and other trade measures as factors that could adversely affect its business, results of operations, financial position, and cash flows.

What Was Disclosed

Nuvectis Pharma filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, reporting 34,388,908 shares outstanding as of October 30, 2026, no revenue generated to date, continued operating losses, and three active product candidates with no pivotal trials completed.